BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 9825577)

  • 21. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
    Link MP; Shuster JJ; Donaldson SS; Berard CW; Murphy SB
    N Engl J Med; 1997 Oct; 337(18):1259-66. PubMed ID: 9345074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.
    Federico M; Moretti G; Gobbi PG; Avanzini P; Cavanna L; Carotenuto M; Lombardo M; Leone G; Pitini V; Abbadessa V
    Leukemia; 1991; 5 Suppl 1():95-101. PubMed ID: 1716340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
    Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
    Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
    Brusamolino E; Passamonti F; Pagnucco G; Castagnola C; Lazzarino M; Bernasconi C
    Haematologica; 1998 Apr; 83(4):323-8. PubMed ID: 9592982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
    Viviani S; Bonfante V; Santoro A; Zanini M; Devizzi L; Di Russo AD; Soncini F; Villani F; Ragni G; Valagussa P; Bonadonna G
    Cancer J Sci Am; 1999; 5(5):275-82. PubMed ID: 10526668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
    Reyes F; Lepage E; Ganem G; Molina TJ; Brice P; Coiffier B; Morel P; Ferme C; Bosly A; Lederlin P; Laurent G; Tilly H;
    N Engl J Med; 2005 Mar; 352(12):1197-205. PubMed ID: 15788496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
    Hattori M; Motomura S; Tomita N; Taguchi J; Tanabe J; Sakai R; Fujisawa S; Fukawa H; Kanamori H; Mouri H; Maruta A; Kodama F; Okubo T
    Rinsho Ketsueki; 1996 Feb; 37(2):101-8. PubMed ID: 8852026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
    Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.